Search Results

Calliditas Therapeutics AB announced that the company now controls 100% of the share capital of Genkyotex SA, after the completion of a centralized squeeze out offer to all minority shareholders.

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing potential risks to the public.

Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA (“Genkyotex”) (Euronext Paris & Brussels: FR0013399474 - GKTX) in an off-market transaction. On August 13, 2020 , Calliditas announced that it had entered into an agreeme

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX - CALTX; NASDAQ - CALT) submitted a simplified public mandatory offer to the shareholders of Genkyotex on 26 November 2020 . After the end of the acceptance period on December 11 , Calliditas now controls 86.2 percent of the shares in Genkyotex. Calliditas acquired 7,2

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s blockbuster Hemlibra.